方法：回顾性分析。经眼科常规检查、荧光素眼底血管造影(FFA)、相干光断层扫描(OCT)检查确诊为湿性AMD的患者20例22眼，给予所有患眼玻璃体腔注射10mg/mL康柏西普0.5mg，每月注射1次，连续3次为初始治疗，后根据病情需要决定是否重复治疗。每月随访1次，随访观察≥6mo。对比分析治疗前后患眼最佳矫正视力(BCVA)、中心视网膜厚度(CRT)及黄斑区脉络膜新生血管(CNV)病灶渗漏变化情况。

结果：治疗后1、3、6mo患眼平均BCVA(LogMRA)均较治疗前提高，差异具有统计学意义(P<0.01)。治疗后1、3、6mo患眼平均CRT均较治疗前降低，差异具有统计学意义(P<0.01)。末次随访时，FFA检查，黄斑区CNV病灶渗漏消失20眼(90%)； 渗漏减轻2眼(9%)。随访期间未见与治疗相关的严重眼部并发症及全身严重不良反应发生。

结论：临床实际应用玻璃体腔注射康柏西普治疗湿性AMD可提高患眼视力，降低患眼CRT，抑制新生血管渗漏，无与治疗相关的不良反应发生。

METHODS: Retrospective analysis. A total of 20 patients involving 22 eyes were diagnosed of wet AMD and confirmed by routine ophthalmic examination, fundus fluorescein angiography(FFA)and optical coherence tomography. All these affected eyes received intravitreal injection of 10 mg/ml of 0.5mg Conbercept, once monthly, for 3 successive times during the initial treatment. The need for repeated treatment was determined according to patients' disease conditions. The patients were followed up once monthly for ≥6mo. The changes in best corrected visual acuity(BCVA), central retinal thickness(CRT)and choroidal neovascularization(CNV)lesion leakage of the affected eyes before and after treatment were compared and analyzed.

RESULTS:Within 1, 3 and 6mo after treatment, the mean BCVA(logMAR)of the affected eyes increased when compared with before treatment; the difference was statistically significant(P<0.01). In 1, 3 and 6mo after treatment, the mean CRT of the affected eyes decreased when compared with before treatment; the difference was statistically significant(P<0.01). During the last follow-up, FFA showed that macular CNV lesion leakage disappeared in 20 eyes(90%)while leakage mitigated in 2 eyes(9%). During the follow-up, there were no treatment-related serious ocular complications and systemic serious adverse reactions.

CONCLUSION:Clinically, intravitreal injection of Conbercept for the treatment of wet AMD can increase visual acuity of the affected eyes. It also can decrease CRT of the affected eyes, and inhibit neovascular leakage. There are no treatment-related adverse reactions.